Complete Remission of Third Recurrence of Acute Myeloid Leukemia after Treatment with Imatinib (STI-571)

M. Schittenhelm Department of Haematology/Oncology, University of Tübingen, Medical School, D-72076, Tübingen, Germany

O. Aichele Department of Haematology/Oncology, University of Tübingen, Medical School, D-72076, Tübingen, Germany

S.M. Kröber Institute of Pathology, University of Tübingen, D-72076, Tübingen, Germany

T. Brümmendorf Department of Haematology/Oncology, University of Tübingen, Medical School, D-72076, Tübingen, Germany

L. Kanz Department of Haematology/Oncology, University of Tübingen, Medical School, D-72076, Tübingen, Germany

C. Denzlinger Department of Haematology/Oncology, University of Tübingen, Medical School, D-72076, Tübingen, Germany

References

Savage, D.G. and Antman, K.H. (2002) "Imatinib mesylate—a new oral targeted therapy", N. Engl. J. Med. 346, 683–693.
PubMed Web of Science ®Google Scholar
Denzlinger, C., Bowen, D., Benz, D., Gelly, K., Bragger, W. and Kanz, L. (2000) "Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukemia", Br J. Haematol. 108, 93–95.
PubMed Web of Science ®Google Scholar
Sievers, EL., Larson, RA., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, L.M., Berger, M.S., Eten, C.B., Loken, ma., van Dongen, J.J.M., Bernstein, ID. and Appelbaum, F.R. (2001) "Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse", J. Clin. Oncol. 19, 3244–3254.
PubMed Web of Science ®Google Scholar
Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Tos, A.G. and Mandelli, F. (1994) "Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia", Blood 84, 2158–2163.
PubMed Web of Science ®Google Scholar
Radsak, M.P., Salih, RR., Saler, M., Kanz, L. and Denzlinger, C. (2002) "Sustained complete remission of recurrent acute myeloid leukemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenace", Leukemia 16, 1870 —1871.
PubMed Web of Science ®Google Scholar
Heinrich, M.C., Griffith, J., Druker, B., Wait, CL., Ott, K.A. and Zigler, A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STI-571, a selective tyrosine kinase inhibitor", Blood 96, 925–932.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Complete Remission of Third Recurrence of Acute Myeloid Leukemia after Treatment with Imatinib (STI-571)

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Complete Remission of Third Recurrence of Acute Myeloid Leukemia after Treatment with Imatinib (STI-571)

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date